Eva Colás

1.5k total citations
30 papers, 751 citations indexed

About

Eva Colás is a scholar working on Obstetrics and Gynecology, Molecular Biology and Cancer Research. According to data from OpenAlex, Eva Colás has authored 30 papers receiving a total of 751 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Obstetrics and Gynecology, 15 papers in Molecular Biology and 11 papers in Cancer Research. Recurrent topics in Eva Colás's work include Endometrial and Cervical Cancer Treatments (15 papers), Ovarian cancer diagnosis and treatment (5 papers) and Extracellular vesicles in disease (4 papers). Eva Colás is often cited by papers focused on Endometrial and Cervical Cancer Treatments (15 papers), Ovarian cancer diagnosis and treatment (5 papers) and Extracellular vesicles in disease (4 papers). Eva Colás collaborates with scholars based in Spain, Palestinian Territory and Netherlands. Eva Colás's co-authors include Antonio Gil‐Moreno, Xavier Matías‐Guiu, Cristian P. Moiola, Sílvia Cabrera, Daniela Annibali, Gema Moreno‐Bueno, Miguel Abal, Frédéric Amant, Jaume Reventós and Elena Martínez-García and has published in prestigious journals such as SHILAP Revista de lepidopterología, Oncogene and Scientific Reports.

In The Last Decade

Eva Colás

27 papers receiving 746 citations

Peers

Countries citing papers authored by Eva Colás

Since Specialization

Citations

This map shows the geographic impact of Eva Colás's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eva Colás with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eva Colás more than expected).

Fields of papers citing papers by Eva Colás

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eva Colás. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eva Colás. The network helps show where Eva Colás may publish in the future.

Co-authorship network of co-authors of Eva Colás

This figure shows the co-authorship network connecting the top 25 collaborators of Eva Colás. A scholar is included among the top collaborators of Eva Colás based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eva Colás. Eva Colás is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	BORA overexpression promotes epithelial–mesenchymal transition and metastasis in ovarian cancer: Unveiling a novel therapeutic target for advanced disease 2025 ·Clinical and Translational Medicine ·(unknown), (unknown), (unknown), Mariana Köber, (unknown), Nora Ventosa, (unknown), Assumpció Pérez‐Benavente, Antonio Gil‐Moreno, Eva Colás, Juan Moróte, Miguel F. Segura, Olga Méndez, Anna Santamaría	1
2	It takes two to tango: importance of oestrogen receptor and progesterone receptor in endometrial cancer 2025 ·The Lancet Oncology ·(unknown), Vít Weinberger, Eva Colás, Camilla Krakstad, Johanna M.A. Pijnenborg, Willem Jan van Weelden	0
3	Molecular profile is a strong predictor of the pattern of recurrence in patients with endometrial cancer 2024 ·International Journal of Gynecological Cancer ·(unknown), (unknown), (unknown), (unknown), (unknown), Josep Castellví, Eva Colás, Antonio Gil‐Moreno, Sílvia Cabrera	7
4	Screening Strategies to Improve Early Diagnosis in Endometrial Cancer 2024 ·Journal of Clinical Medicine ·Sílvia Cabrera, (unknown), Sonia Baulies, Antonio Gil‐Moreno, Eva Colás	3
5	195P Preclinical efficacy of the trastuzumab duocarmazine SYD985 as monotherapy or in combination with the PARP inhibitor niraparib in HER2-expressing endometrial cancer 2024 ·Annals of Oncology ·Eva Colás, Cristian P. Moiola, (unknown), (unknown), (unknown), (unknown), (unknown), Luis A. Salazar, Sílvia Cabrera, (unknown), Patrick G. Groothuis, Antonio Gil‐Moreno	0
6	Noninvasive detection of microsatellite instability in patients with endometrial cancer 2023 ·International Journal of Cancer ·(unknown), Cristian P. Moiola, Ana Vilar, (unknown), Juan Cueva, Sílvia Cabrera, (unknown), (unknown), Alicia Abalo, Ángel García, Ramón Manuel Lago‐Lestón, Sara S. Oltra, Eva Díaz, Juan Ruiz‐Bañobre, Rafael López‐López, Gema Moreno‐Bueno, Antonio Gil‐Moreno, Eva Colás, Miguel Abal, Laura Muinelo‐Romay	8
7	Endometrial cancer PDX-derived organoids (PDXOs) and PDXs with FGFR2c isoform expression are sensitive to FGFR inhibition 2023 ·npj Precision Oncology ·(unknown), Vanessa Bonazzi, Deborah S. Smith, Cristian P. Moiola, Rohan Lourie, Rebecca F. Rogers, Eva Colás, Antonio Gil‐Moreno, Sophia Frentzas, Naven Chetty, Lewis Perrin, Pamela M. Pollock	11
8	MAP kinase ERK5 modulates cancer cell sensitivity to extrinsic apoptosis induced by death-receptor agonists 2023 ·Cell Death and Disease ·(unknown), Saška Ivanova, Elisenda Alari‐Pahissa, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Eva Colás, Miguel López‐Botet, António Zorzano, José M. Lizcano	9
9	Cervical Fluids Are a Source of Protein Biomarkers for Early, Non-Invasive Endometrial Cancer Diagnosis 2023 ·Cancers ·Elena Martínez-García, (unknown), Antoine Lesur, Gunnar Dittmar, Antonio Gil‐Moreno, Sílvia Cabrera, Eva Colás	10
10	Genomic Validation of Endometrial Cancer Patient-Derived Xenograft Models as a Preclinical Tool 2022 ·International Journal of Molecular Sciences ·(unknown), (unknown), (unknown), (unknown), (unknown), Genı́s Parra, Ángel García, (unknown), Sílvia Cabrera, Eva Colás, Antonio Gil‐Moreno, Cristian P. Moiola	8
11	The ERK5/NF-κB signaling pathway targets endometrial cancer proliferation and survival 2022 ·Cellular and Molecular Life Sciences ·Nora Diéguez-Martínez, (unknown), Guillermo Yoldi, (unknown), (unknown), (unknown), (unknown), (unknown), Héctor Perez‐Montoyo, José R. Bayascas, Eva Colás, Xavier Dolcet, José M. Lizcano	21
12	In silico Approach for Validating and Unveiling New Applications for Prognostic Biomarkers of Endometrial Cancer 2021 ·Cancers ·(unknown), Elena Martínez-García, Gunnar Dittmar, Petr V. Nazarov, (unknown), Sílvia Cabrera, Antonio Gil‐Moreno, Eva Colás	8
13	Small-Molecule Inhibitors (SMIs) as an Effective Therapeutic Strategy for Endometrial Cancer 2020 ·Cancers ·(unknown), Cristian P. Moiola, (unknown), (unknown), Antonio Gil‐Moreno, Xavier Matías‐Guiu, Eva Colás, Núria Eritja	17
14	Prognostic Biomarkers in Endometrial Cancer: A Systematic Review and Meta-Analysis 2020 ·Journal of Clinical Medicine ·(unknown), Elena Martínez-García, Gunnar Dittmar, Antonio Gil‐Moreno, Sílvia Cabrera, Eva Colás	74
15	Genomic Profiling of Uterine Aspirates and cfDNA as an Integrative Liquid Biopsy Strategy in Endometrial Cancer 2020 ·Journal of Clinical Medicine ·(unknown), Eva Díaz, Cristian P. Moiola, Lorena Alonso‐Alconada, Alba Ferreirós, Alicia Abalo, (unknown), Sara S. Oltra, Javier De Santiago, Sílvia Cabrera, (unknown), (unknown), (unknown), Juan Cueva, Eva Colás, Ana Vilar, Antonio Gil‐Moreno, Miguel Abal, Gema Moreno‐Bueno, Laura Muinelo‐Romay	21
16	EV-associated miRNAs from pleural lavage as potential diagnostic biomarkers in lung cancer 2019 ·Scientific Reports ·(unknown), Cristian P. Moiola, Sónia Gatius, Sarah Bonnin, María Ruiz-Miró, Esperanza González, (unknown), (unknown), Antonio Gil‐Moreno, Juan Manuel Falcón‐Pérez, Julia Ponomarenko, José M. Porcel, Xavier Matías‐Guiu, Eva Colás	32
17	Targeted Proteomics Identifies Proteomic Signatures in Liquid Biopsies of the Endometrium to Diagnose Endometrial Cancer and Assist in the Prediction of the Optimal Surgical Treatment 2017 ·Clinical Cancer Research ·Elena Martínez-García, Antoine Lesur, Laura Devis, Sílvia Cabrera, Xavier Matías‐Guiu, Marc Hirschfeld, (unknown), Jan van Oostrum, M. Casares de Cal, Antonio Gómez‐Tato, Jaume Reventós, Bruno Domon, Eva Colás, Antonio Gil‐Moreno	50
18	Integrated genome analysis of uterine leiomyosarcoma to identify novel driver genes and targetable pathways 2017 ·International Journal of Cancer ·(unknown), Matthieu Moisse, Jeroen Depreeuw, Daniela Annibali, Eva Colás, Antonio Gil‐Moreno, Jutta Huvila, Olli Carpén, Michal Zikán, Xavier Matías‐Guiu, Philippe Moerman, Sabrina Croce, Diether Lambrechts, Frédéric Amant	57
19	Genetic analysis of uterine aspirates improves the diagnostic value and captures the intra-tumor heterogeneity of endometrial cancers 2016 ·Modern Pathology ·Alba Mota, Eva Colás, Pablo García‐Sanz, Irene Campoy, Alejandro Rojo‐Sebastián, Sónia Gatius, Ángel García, Luis Chiva, Sonsoles Alonso, Antonio Gil‐Moreno, (unknown), Berta Díaz‐Feijoó, August Vidal, (unknown), Marcin Bobiński, Rafael López‐López, Miguel Abal, Jaume Reventós, Xavier Matías‐Guiu, Gema Moreno‐Bueno	33
20	Endometrial carcinoma: molecular alterations involved in tumor development and progression 2012 ·Oncogene ·Andrée Yeramian, Gema Moreno‐Bueno, Xavier Dolcet, Lluís Catasús, Miguel Abal, Eva Colás, Jaume Reventós, José Palacios, Jaime Prat, Xavier Matías‐Guiu	135

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact